StockData
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) stock

PHATNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 4/30
$6.06−0.17 (-2.73%)

Close on Nov 13, 2026Market cap $492.63MP/E –Yield –

Phathom Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Phathom Pharmaceuticals's ebitda for the twelve months ending Sep 30, 2026 was -$24.98M. For fiscal 2025 it was -$159.35M. The highest annual figure on record is -$106.21M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$159.35M–
FY2024Dec 31, 2024-$276.67M–
FY2023Dec 31, 2023-$166.74M–
FY2022Dec 31, 2022-$171.82M–
FY2021Dec 31, 2021-$134.56M–
FY2020Dec 31, 2020-$125.34M–
FY2019Dec 31, 2019-$106.21M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$35.00K–
Q2 FY2026Jun 30, 2026-$3.85M–
Q1 FY2026Mar 31, 2026-$15.37M–
Q4 FY2025Dec 31, 2025-$5.80M–
Q3 FY2025Sep 30, 2025-$15.12M–
Q2 FY2025Jun 30, 2025-$59.75M–
Q1 FY2025Mar 31, 2025-$78.69M–
Q4 FY2024Dec 31, 2024-$59.22M–
Q3 FY2024Sep 30, 2024-$70.60M–
Q2 FY2024Jun 30, 2024-$77.10M–
Q1 FY2024Mar 31, 2024-$69.74M–
Q4 FY2023Dec 31, 2023-$69.69M–
Q3 FY2023Sep 30, 2023-$35.56M–
Q2 FY2023Jun 30, 2023-$31.60M–
Q1 FY2023Mar 31, 2023-$29.93M–
Q4 FY2022Dec 31, 2022-$46.47M–
Q3 FY2022Sep 30, 2022-$42.35M–
Q2 FY2022Jun 30, 2022-$45.21M–
Q1 FY2022Mar 31, 2022-$37.78M–
Q4 FY2021Dec 31, 2021-$32.91M–
Q3 FY2021Sep 30, 2021-$33.01M–
Q2 FY2021Jun 30, 2021-$35.19M–
Q1 FY2021Mar 31, 2021-$33.46M–
Q4 FY2020Dec 31, 2020-$52.33M–
Q3 FY2020Sep 30, 2020-$32.74M–
Q2 FY2020Jun 30, 2020-$19.94M–
Q1 FY2020Mar 31, 2020-$20.32M–
Q4 FY2019Dec 31, 2019-$15.69M–

More Phathom Pharmaceuticals figures

See a number that looks wrong?